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Long noncoding RNAs (lncRNAs) are transcripts longer than 200
nucleotides, located within the intergenic stretches or overlapping
antisense transcripts of protein coding genes. LncRNAs are involved
in numerous biological roles including imprinting, epigenetic regula-
tion, apoptosis, and cell cycle. To determine whether lncRNAs are
associated with clinical features and recurrent mutations in older
patients (aged ≥60 y) with cytogenetically normal (CN) acute mye-
loid leukemia (AML), we evaluated lncRNA expression in 148 un-
treated older CN-AML cases using a custom microarray platform.
An independent set of 71 untreated older patients with CN-AML
was used to validate the outcome scores using RNA sequencing.
Distinctive lncRNA profiles were found associated with selected
mutations, such as internal tandem duplications in the FLT3 gene
(FLT3-ITD) and mutations in the NPM1, CEBPA, IDH2, ASXL1, and
RUNX1 genes. Using the lncRNAs most associated with event-free
survival in a training cohort of 148 older patients with CN-AML, we
derived a lncRNA score composed of 48 lncRNAs. Patients with an
unfavorable compared with favorable lncRNA score had a lower
complete response (CR) rate [P < 0.001, odds ratio = 0.14, 54%
vs. 89%], shorter disease-free survival (DFS) [P < 0.001, hazard ratio
(HR) = 2.88] and overall survival (OS) (P < 0.001, HR = 2.95). The
validation set analyses confirmed these results (CR, P = 0.03; DFS,
P= 0.009; OS, P= 0.009). Multivariable analyses for CR, DFS, and OS
identified the lncRNA score as an independent marker for outcome.
In conclusion, lncRNA expression in AML is closely associated with
recurrent mutations. A small subset of lncRNAs is correlated
strongly with treatment response and survival.
lncRNAs | acute myeloid leukemia | outcome
Acute myeloid leukemia (AML) is diagnosed most often inolder adults (age ≥ 60 y) who often have a worse prognosis,
with long-term overall survival (OS) rates of only 5–16% (1–3).
The reasons for the poor outcome of older patients relate to
higher frequencies of secondary disease (e.g., AML diagnosed
after hematologic disorders and/or therapy-related disease), ad-
verse cytogenetics (e.g., complex karyotype), comorbid conditions,
and poor performance status (3–7). Nonrandom chromosomal
abnormalities (e.g., deletions, translocations) are identified in
50–55% of all older patients with primary AML (3–8). In contrast,
about 45–50% of all AML cases are cytogenetically normal
(CN-AML) when assessed using conventional banding analysis
(3–8). Recent work has identified novel genetic alterations, in-
cluding gene mutations and changes in gene expression in
CN-AML that have improved the classification and risk stratifi-
cation of this large subgroup of patients (9, 10). Whereas most of
these studies were performed in younger patients with CN-AML,
some studies have investigated the prognostic significance of ge-
netic alterations in older patients (11–19). Our group reported
that nucleophosmin (nucleolar phosphoprotein B23, numatrin)
(NPM1) mutations are associated with a more favorable outcome in
older patients with CN-AML (11), whereas fms-related tyrosine
kinase 3 (FLT3) internal tandem duplications (FLT3-ITDs) and
mutations in the additional sex combs like transcriptional regu-
lator 1 (ASXL1), runt-related transcription factor 1 (RUNX1) and
DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A), which
affect arginine codon 882 (R882-DNMT3A), are independently
associated with worse disease-free survival (DFS) and OS (12–15).
We further showed that high expression levels of the brain and
acute leukemia, cytoplasmic (BAALC), v-ets avian erythroblas-
tosis virus E26 oncogene homolog (ERG), meningioma (dis-
rupted in balanced translocation) 1 (MN1), and DNA (cytosine-
5-)-methyltransferase 3 beta (DNMT3B) genes are associated with
unfavorable outcome in older patients with CN-AML (16–18).
Significance
Long noncoding RNAs (lncRNAs) are involved in numerous bio-
logical roles including epigenetic regulation, apoptosis, and cell
cycle. Whereas lncRNAs contribute to epigenetic gene regula-
tion, metastasis, and prognosis in solid tumors, their role in acute
myeloid leukemia (AML) has not been hitherto reported. Here,
we show that lncRNA expression profiles are associated with
recurrent mutations, clinical features, and outcome in AML.
A fraction of these lncRNAs may have a functional role in
leukemogenesis. Furthermore, lncRNAs could be used as bio-
markers for outcome in AML. The identification of patients likely
to achieve complete remission with standard therapy alone,
based on lncRNA expression, is a significant advance potentially
sparing such patients from other toxicities and focusing in-
vestigational approaches on postremission studies.
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In addition to genetic alterations in protein coding genes,
aberrant expression of noncoding RNAs plays a critical role in
leukemia initiation and outcome prediction (19). MicroRNAs
(miRNAs) constitute the first class of noncoding RNAs, whose
expression was found widely dysregulated in AML and associated
with clinical features including outcome (20, 21). We reported
unique miRNA expression signatures associated with NPM1,
RUNX1, and tet methylcytosine dioxygenase 2 (TET2) mutations
in older patients with CN-AML (11, 15, 22). High levels of miR-
155 and miR-3151 were also found to be associated with worse
outcome in older patients with CN-AML (23, 24).
More recently, another class of noncoding RNAs named long
noncoding RNAs (lncRNAs) was discovered (25). LncRNAs are
trancripts longer than 200 nucleotides, located within the inter-
genic stretches or overlapping antisense transcripts of protein
coding genes (25, 26). LncRNA genes are typically shorter than
protein-coding genes and are predominantly transcribed by RNA
polymerase II (26). LncRNAs have emerged as important reg-
ulators of gene expression, showing cell-specific expression pat-
terns and subcellular localization and are involved in many
biological roles including imprinting, epigenetic regulation, ap-
optosis, and cell cycle (26, 27). The well-characterized lncRNA
HOX transcript antisense RNA (HOTAIR) has been found to
be up-regulated in multiple cancers including breast, colorectal,
hepatic, gastric, and pancreatic cancers (28–33). HOTAIR
modulates chromatin structures by serving as a scaffold and
recruiting histone modifiers (28). In breast cancer, HOTAIR
promotes cancer cell invasion and metastasis in vivo through
epigenetic silencing of metastasis suppressor genes (29–33). In
patients with nonsmall cell lung cancer, high expression of the
lncRNA metastasis-associated lung adenocarcinoma transcript 1
(MALAT1) was associated with metastases and poor survival,
indicating its importance as a prognostic biomarker (34).
Whereas lncRNAs contribute to epigenetic gene regulation,
metastasis, and prognosis in solid tumors, their role in AML has
not been reported to date. In this study, we analyzed a large set
of older patients with CN-AML using custom lncRNA micro-
arrays and RNA sequencing (RNA-seq) to investigate whether
lncRNA expression is associated with clinical features, molecular
abnormalities, and outcome.
Results
LncRNA Signatures Associated with Recurrent Mutations in CN-AML.
To identify lncRNAs associated with recurrent mutations in CN-
AML, we compared mutated and wild-type (WT) samples in the
training set of 148 older patients with de novo CN-AML. For all
of the signatures, we used P < 0.001 and fold change (FC) ≥ 1.5
(Table S1 and SI Methods and Data show patient clinical and
molecular features).
Fig. 1. Heat map of the lncRNA-expression signature associated with NPM1, FLT3-ITD, and CEBPA mutations in older patients with primary CN-AML. (A) The
heat map shows expression levels of 205 probe sets found differentially expressed between NPM1-mutated (mut) (n = 84) vs. NPM1 wild-type (WT) (n = 64)
cases. (B) The heat map shows expression levels of 140 probe sets found differentially expressed between FLT3-ITD (n = 48) vs. FLT3-WT (n = 100) cases. (C) The
heat map shows expression levels of 57 probe sets found differentially expressed between CEBPA-mut (n = 18) vs. CEBPA-WT (n = 130) cases. Rows represent
probe sets and columns, individual patients. Patients are grouped according to NPM1, FLT3-ITD, and CEBPA mutation status, and genes are ordered by hi-
erarchical cluster analysis. Expression values of the probe sets are represented by color: green represents expression less than the median value for the given
probe set, and red, expression greater than the median value for the given probe set.
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NPM1 LncRNA Signature. Patients with NPM1-mutated CN-AML
(n = 84) have a strong and distinctive lncRNA signature com-
posed of 205 probes corresponding to 180 lncRNAs (Fig. 1A and
Table S2). Among the up-regulated lncRNAs, several were an-
tisense transcripts of HOX genes (e.g., HOXB-AS3, MEIS1-AS2)
that have been reported to be up-regulated in NPM1-mutated
AML (35). The plasmacytoma variant translocation 1 (PVT1)
lncRNA, which is expressed at higher levels in NPM1-mutated
patients, is associated with poor prognosis in colorectal cancer via
apoptosis inhibition (36). Another study reported that PVT1 si-
lencing in breast and ovarian cancer cell lines resulted in a strong
proliferation and apoptotic response (37). The coiled-coil domain
containing 26 (CCD26) lncRNA, also up-regulated in the NPM1-
mutated subset, is a retinoic acid-dependent modulator of mye-
loid cell differentiation and death (38). It has been reported that
the genotype “mutant NPM1 without FLT3-ITD” appears to be
a marker predictive for response to all-trans retinoic acid given as
an adjunct to intensive chemotherapy (39).
FLT3-ITD LncRNA Signature. We identified 119 lncRNAs (from 140
probes) associated with the presence of FLT3-ITD mutations (n =
48) compared with FLT3-WT (n = 100) (Fig. 1B and Table S3).
Because NPM1 and FLT3-ITD mutations frequently coexist,
there was considerable overlap in their lncRNA signatures
(65 probes) (9, 10). Among the 75 probes that were present only in
the FLT3-ITD signature, there were two probes corresponding to
Wilms tumor 1 antisense RNA (WT1-AS) lncRNA. WT1-AS has
been reported to interact with WT1 sense RNA resulting in WT1
protein up-regulation (40). Interestingly, WT1 RNA expression
correlates with FLT3-ITD expression in patients with AML (41).
Alternative splicing of WT1-AS has been found in AML. Whereas
the functional significance of this finding is unknown, aberrations
in alternative splicing have been suggested as contributing factors
in the development of various diseases including cancer (42).
CEBPA LncRNA Signature. We identified a signature of 51 lncRNAs
(from 57 probes) in patients with CCAAT/enhancer binding pro-
tein (C/EBP), alpha (CEBPA)-mutated CN-AML (n = 18) (Fig.
1C and Table S4). The most down-regulated lncRNAs in CEBPA-
mutated leukemia samples corresponded to HOXB-AS3, already
identified as strongly associated with NPM1 mutation. This finding
was expected, because CEBPA mutations occur preferentially
(>90%) in patients with wild-type NPM1 (9, 10). Among the up-
regulated lncRNAs (n = 50) in patients with CEBPA-mutated CN-
AML is urothelial cancer associated 1 (UCA-1), which has been
related to more aggressive disease or metastatic potential in
bladder and tongue squamous cell carcinoma (43, 44).
IDH1 and IDH2 LncRNA Signatures. Patients’ samples with R132
mutations in isocitrate dehydrogenase 1 (NADP+), soluble
(IDH1R132) (n = 14) had only two differentially expressed
lncRNAs: DLEU2 (up-regulated in IDH1R132) and RP11-
147N17.1 (down-regulated in IDH1R132). Regarding isocitrate
dehydrogenase 2 (NADP+), mitochondrial (IDH2) mutations,
22 lncRNAs were differentially expressed between IDH2-
mutated (IDH2R140 in 31 cases and IDH2R172 in 9 cases) and IDH2-
WT cases (n = 108) (Table S5). Among these lncRNAs, 19 were
differentially expressed in IDH2R172 and 8 in IDH2R140 cases.
Altogether, the data indicate that there are lncRNAs associated
with both types of IDH2 mutations, whereas some lncRNAs
are characteristic of only one type of mutation. For example,
LOC100505854 is overexpressed in the IDH2R172 subset, but not
in the IDH2R140 samples. This lncRNA associates with and re-
presses the tumor suppressor CDKN1A/p21 promoter by re-
cruiting polycomb complex proteins (45).
RUNX1 LncRNA Signature. In our patient cohort, RUNX1mutations
were almost mutually exclusive with NPM1 mutations (Fig. S1),
which themselves have strong, characteristic lncRNA gene-
expression signatures. To avoid confounding effects due to the
NPM1 mutations, we performed a two-class analysis (RUNX1-
mutated vs. WT) blocking for NPM1 mutation cases and using
a randomized block design, as described in SI Methods and Data.
Using this approach, we identified a signature comprising 76
lncRNAs from 83 probes (Table S6). Among the lncRNAs up-
regulated in RUNX1-mutated AMLs, several were located in the
proximity of genes characteristic of lymphoid cells such as the
B-cell linker (BLNK) and the immunoglobulin heavy locus (IGH)
complex. We previously reported that patients with RUNX1-
mutated CN-AML exhibit up-regulation of lymphoid genes (15).
Another up-regulated lncRNA in mutated RUNX1, vault RNA
1-1 (VTRNA1-1) has been associated with multidrug resistance
(46). This could be relevant because patients with RUNX1-
mutated CN-AML have a particularly poor outcome (15).
ASXL1 LncRNA Signature. Because ASLX1 mutations were found
exclusively in NPM1-WT cases (Fig. S1) (9, 10, 15), we again
performed the lncRNA analysis blocking for NPM1-mutated
cases as described above. We identified only two differentially
expressed lncRNAs in ASXL1-mutated samples; PR11-1055B8.4
was up-regulated 22-fold, whereas the ankyrin repeat domain 20
family, member A5, pseudogene (ANKRD20A5P) was down-
regulated twofold in patients with ASXL1 mutations.
LncRNAs Profiles Associated with AML with Tyrosine Kinase Domain
Mutations in the FLT3 Gene, Partial Tandem Duplications of the MLL
Gene, and DNMT3A, TET2, and WT1 Mutations. We did not identify
significant lncRNAs associated with tyrosine kinase domain
mutations in the FLT3 gene (n = 16), DNMT3A (n = 47) or TET2
(n = 38) mutations. For WT1 mutations (n = 7) and partial tan-
dem duplications of theMLL gene (n = 9) there were not enough
cases to derive lncRNA signatures with confidence.
Building the Prognostic LncRNA Score. To develop a prognostic
lncRNA score, we used pretreatment frozen bone marrow
(BM) samples from 148 older patients with de novo CN-AML
(Table S1). All patients were treated with intensive cytarabine/
daunorubicin-based frontline therapy on Cancer and Leukemia
Group B (CALGB) treatment protocols and did not receive he-
matopoietic stem cell transplant (HSCT) in first complete re-
sponse (CR) (Table S1 and SI Methods and Data). First, we
identified 48 lncRNAs that were associated with (P < 0.001)
event-free survival (EFS) by univariable Cox analysis (Table S7).
The lncRNA score was derived as a linear combination of the
expression of the 48 lncRNAs as described in Patients and
Methods. We then divided the lncRNA score into quartiles. After
creating the Kaplan–Meier plots for the quartiles, it was evident
that the first quartile separated from the remaining quartiles and
had a significantly better EFS. We therefore classified patients
with scores in the first quartile as “favorable” and the rest as
“unfavorable.” We then evaluated the lncRNA score using a di-
chotomized approach comparing unfavorable with favorable
patients (Table 1). Interestingly, the majority of the 48 lncRNAs
associated with survival do not associate with known prognostic
gene mutations in older patients with CN-AML. Only three of
them do: LOC728606 (up-regulated in NPM1-mutated patients)
and CTA-392E5.1 and BC016361 (both down-regulated in
patients with RUNX1-WT).
Associations of the LncRNA Score with Clinical and Molecular
Characteristics. Patients with an unfavorable lncRNA score had
higher white blood cell (WBC) counts (P = 0.004), and were more
likely to have extramedullary involvement (P = 0.01; Table S1).
Also, the unfavorable lncRNA score was associated with higher
expression ofMN1 (P = 0.003) and miR-3151 (P = 0.01; Table S1).
Prognostic Value of the LncRNA Score.Compared with patients with
a favorable lncRNA score, those with an unfavorable score had
a lower CR rate [P < 0.001, odds ratio (OR) = 0.14, 54% vs.
89%)], and shorter DFS [P < 0.001, hazard ratio (HR) = 2.88;
Fig. 2A and Table 1]. Three years after CR, only 7% of patients
with unfavorable lncRNA were disease-free compared with 39%











of patients with favorable lncRNA. The patients with an un-
favorable lncRNA score also had shorter OS (P < 0.001, HR =
2.95; Fig. 2B and Table 1). The OS rate at 3 y was only 10% for
patients with unfavorable lncRNA compared with 43% for
patients with favorable lncRNA. In multivariable analyses, after
adjusting for BAALC and miR-155 expression status, patients
with an unfavorable lncRNA score had lower CR rates (P =
0.007, OR = 0.19) (Table 2). They also had shorter DFS (P <
0.001, HR = 3.23), after adjusting for the European LeukemiaNet
(ELN) genetic group status (8), and shorter OS (P < 0.001,
HR = 3.62), after adjusting for miR-155 expression and the ELN
genetic group status (Table 2). All statistical analyses were also
performed using the continuous lncRNA score, with similar
results (SI Methods and Data shows the methods and results of
the analyses of continuous lncRNA score).
Validation of the LncRNA Score by RNA-Seq. To validate the lncRNA
score, we performed lncRNA profiling using RNA-seq in pre-
treatment BM and peripheral blood (PB) samples from 71 older
patients with de novo CN-AML. All patients were treated with
intensive cytarabine/daunorubicin-based frontline therapy on
CALGB protocols and did not receive HSCT in first CR. There
were no significant baseline clinical and molecular differences
between the training (n = 148) and validation datasets (n = 71)
(Table S8). To validate the impact of lncRNA scores on CR,
DFS, and OS, we considered 46 of the 48 survival-associated
lncRNAs that were used in the training set, because two lncRNAs
were not detected by RNA-seq. The RNA-seq score was derived
as a linear combination of the expression of the 46 lncRNAs as
described in Patients and Methods. Because we used a different
platform (RNA-seq), we explored different approaches to select
the best cut point (quartiles vs. median). After creating the
Kaplan–Meier plots for quartiles, it was evident that the first
and second quartiles grouped together and separated well from
the third and fourth quartiles and had a significantly better EFS.
We therefore classified patients with scores above the median
as favorable and patients below the median as unfavorable.
Patients with an unfavorable lncRNA score had a lower CR rate
(P = 0.03, 63% vs. 86%) compared with patients with favorable
lncRNA score and had shorter DFS (P = 0.009) and OS (P =
0.009) (Fig. 2 C and D).
Discussion
Despite the advances in understanding both the biology and risk
stratification of adult AML, outcome is still poor, particularly in
older patients aged 60 y or older (2–6). Whereas recent studies
have reported that clinical outcome of older patients with CN-
AML is influenced by several recurrent mutations, patients with
apparently identical cytogenetic and molecular “makeup” do not
have uniform outcomes (11–19). This may result from additional
undiscovered genetic alterations, which may identify smaller,
clinically meaningful patient groups for which it is possible to
identify specific therapeutic targets.
In this work, we investigated the associations of lncRNA ex-
pression with clinical characteristics, recurrent mutations, and
outcome in older patients with CN-AML. We identified distinctive
lncRNA expression signatures associated with the most common
recurrent mutations in CN-AML. Patients with NPM1 mutations
exhibit one of the strongest lncRNA signatures, as evidenced by
higher lncRNA fold change and lower false discovery rates. It has
been reported that NPM1-mutated CN-AML exhibits unique and
strong mRNA and miRNA expression profiles characterized by
HOX gene and miR-10 family overexpression and CD34 negativity
(11, 47). Because ∼40% of lncRNAs intersect protein-coding loci
and exhibit a strong pattern of coexpression (26), we found many
up-regulated lncRNAs overlapping antisense transcripts of HOX
genes (e.g., HOXB-AS3) in the NPM1-mutated lncRNA signa-
ture. A previous study has shown that the HOX antisense tran-
script, known as HOTAIR, is transcribed antisense to the HOXC
locus and despite its genomic location, it has little effect on the
regulation of the sense transcript (28). Instead, HOTAIR was
shown to function in trans to negatively regulate HOXD via in-
creased polycomb repressive complex 2 (PRC2) occupancy at the
HOXD locus (28). A second group reported that HOX antisense
intergenic RNA myeloid-specific 1 (HOTAIRM1) is transcribed
antisense to the HOXA genes (between HOXA1 and HOXA2),
shows myeloid-specific expression and is up-regulated during
granulocytic differentiation (48). Knockdown of HOTAIRM1
Table 1. Treatment outcomes according to the lncRNA score status in 148 older (aged ≥60 y) patients with de novo
CN-AML
End point
Favorable lncRNA score Unfavorable lncRNA score
(n = 37) (n = 111) P* OR/HR (95% CI)
Complete response, no. (%) 33 (89) 60 (54) <0.001 0.14 (0.05–0.43)
Disease-free survival <0.001 2.88 (1.74–4.76)
Median, y 1.5 0.7
% disease-free at 3 y (95% CI) 39 (23–55) 7 (2–15)
% disease-free at 5 y (95% CI) 36 (32–52) 2 (0–8)
Overall survival <0.001 2.95 (1.89–4.61)
Median, y 2.2 0.9
% alive at 3 y (95% CI) 43 (27–58) 10 (6–17)
% alive at 5 y (95% CI) 41 (25–56) 5 (2–10)
CI, confidence interval; HR, hazard ratio; OR, odds ratio.
*P values for categorical variables are from Fisher’s exact test, P values for the time to event variables are from the log-rank test.
Fig. 2. Comparison of disease-free survival (DFS) and overall survival (OS)
according to the lncRNA score in two datasets of older patients with CN-
AML. Training dataset (n = 148) DFS (A) and OS (B). Validation dataset (n =
71) DFS (C) and OS (D).
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quantitatively blunted retinoic acid-induced expression of HOXA1
and HOXA4 during the myeloid differentiation of NB4 cells and
selectively attenuated induction of transcripts for the myeloid
differentiation genes ITGAM (CD11b) and ITGB2 (CD18) (48).
These findings suggest that HOTAIRM1 plays a role in myelo-
poiesis through modulation of gene expression in the HOXA
cluster. Whereas the functional role of these HOX antisense
transcripts associated with NPM1 mutations is unknown, we hy-
pothesize that these transcripts may regulate overlapping HOX
protein coding genes or other HOX genes located in different loci.
In addition, we report here lncRNA expression profiles associ-
ated with other frequent mutations in CN-AML, such as FLT3-
ITD, CEBPA, IDH2, RUNX1, and ASXL1 mutations. Remarkably,
no lncRNA profiles were found associated with two frequent mu-
tations in older patients with CN-AML, DNMT3A and TET2, both
of which are involved in epigenetic regulation (14, 22). The fact
that lncRNA profiles were “mutually exclusive” with these muta-
tions is suggestive of a shared effect within the epigenetic pathway.
The association of the WT1-AS lncRNA with FLT3-ITD is inter-
esting because the expression of the nearWT1 protein-coding gene
is also increased in this molecular subtype of CN-AML, and splic-
ing alterations have been described for WT1-AS (41, 42). It re-
mains to be investigated whether this event represents just a
coexpression phenomenon or has a truly functional role.
Regardless of whether lncRNAs are functional or not, lncRNAs
might have prognostic applications in AML. Several lncRNAs have
been associated with outcome in solid tumors (29–34). How-
ever, to our knowledge, there are no published reports for he-
matological malignancies, including AML. To minimize the
impact of type of treatment in AML outcome interpretation, we
analyzed a cohort of patients that were all treated with cytar-
abine/daunorubicin-based induction chemotherapy and did not
receive HSCT in first CR. Using the lncRNAs most associated
with EFS in a training cohort of 148 older patients with CN-
AML, we derived a score of 48 lncRNAs. Patients with a favor-
able lncRNA score had a higher CR rate than those with an
unfavorable score (89% vs. 54%; P < 0.001). These results were
reproduced in the validation cohort, which was studied using
a different technical platform. The identification of patients
likely to achieve CR with standard therapy (7 + 3) alone rep-
resents a significant advance, potentially sparing them from
other toxicities associated with experimental induction regimens
and focusing investigational approaches on postremission (allo-
geneic HSCT and eradication of minimal residual disease)
studies. Furthermore, patients with a favorable lncRNA score
exhibit longer DFS and OS than patients with an unfavorable
lncRNA score in both the training and validation cohorts. Mul-
tivariable analyses for CR, DFS, and OS identified the lncRNA
score as an independent marker for outcome. It is remarkable
how the different prognostic mutations associate with distinct
lncRNA profiles. On the other hand, expression levels of the
prognostic lncRNAs mostly do not associate with prognostic
mutations. Indeed, the prognostic lncRNA score has divided
older patients with CN-AML into two groups, which, despite
having very similar frequencies of FLT3-ITD and NPM1 and
CEBPA mutations (all strong prognosticators in CN-AML), have
had significantly different outcomes. Overall, these data indicate
that lncRNAs could be used to predict treatment response and
outcome in older patients with CN-AML. Further studies will be
needed to investigate the prognostic impact of lncRNAs in
younger adults (aged 15–59 y) and children (under 15 y) with de
novo CN-AML.
In summary, here we describe lncRNA profiles in older patients
with CN-AML and their associations with clinical features, mu-
tations, and outcome. Distinctive lncRNA signatures were found
associated with recurrent mutations in CN-AML. Future work is
needed to investigate whether these lncRNAs are functional
and whether they are regulated directly or indirectly by biologic
changes promoted by these specific mutations. Additionally, we
identified a lncRNA score that is strongly associated with out-
come, including treatment response to standard intensive che-
motherapy in older patients with CN-AML. This score could be
used to prospectively identify those patients who are likely to have
high CR rates with standard therapy, while at the same time
treating the remaining patients with novel combination treatment
approaches using targeted therapies to improve their CR rates.
Patients and Methods
Patient Set. Pretreatment frozen BM samples from 148 older (aged ≥60 y)
patients with de novo CN-AML (training set) and 71 pretreatment frozen
samples (52 BM and 19 PB) from older patients with de novo CN-AML
(validation set) were obtained from the CALGB/Alliance leukemia tissue
bank. Informed consent was obtained from the patients in accordance with
the Declaration of Helsinki to procure and bank the cells for future research
according to the institutional review boards of each of the participating
institutions. Patient characteristics are shown in Tables S1 and S8. Cytoge-
netic analyses were performed in CALGB/Alliance approved institutional
laboratories and confirmed by central karyotype review (49), and the
diagnosis of normal karyotype was based on ≥20 metaphase cells ana-
lyzed in BM specimens subjected to short-term (24 h or 48 h) unstimu-
lated cultures. Molecular studies shown in Tables S1 and S8 were performed
as described in SI Methods and Data and elsewhere (11–18). The patients in
the training and validation sets were treated with intensive cytarabine/
daunorubicin-based therapy on one of the CALGB frontline treatment pro-
tocols as described in SI Methods and Data.
Statistical Analyses. Definitions of clinical end points are provided in SI
Methods and Data. The associations of the lncRNA score with baseline
clinical, demographic, and molecular features were compared using the
Wilcoxon rank sum and Fisher’s exact tests for continuous and categorical
variables, respectively. Estimated probabilities of DFS and OS were calcu-
lated using the Kaplan–Meier method, and the log-rank test evaluated
differences between survival distributions. Logistic regression was used for
CR to calculate univariable ORs and the Cox proportional hazards model
was used for DFS and OS to calculate univariable HRs. All statistical anal-
yses were performed by the Alliance for Clinical Trials in Oncology Sta-
tistics and Data Center using SAS 9.3 and TIBCO Spotfire S+ 8.2.
Multivariable Analyses. Multivariable logistic regression models were gener-
ated for attainment of CR, and multivariable proportional hazards models
were constructed for DFS and OS, using a limited forward selection pro-
cedure. Variables significant at α = 0.20 from the univariable analyses
were considered for multivariable analyses (see SI Methods and Data for
Table 2. Multivariable analysis of outcome according to the lncRNA score in older patients with CN-AML
Complete response Disease-free survival Overall survival
Variable Categories OR 95% CI P HR 95% CI P HR 95% CI P
LncRNA score Unfavorable vs. favorable 0.19 0.06–0.63 0.007 3.23 1.93–5.43 <0.001 3.62 2.26–5.78 <0.001
BAALC expression group High vs. low 0.17 0.07–0.40 <0.001 — — — — — —
miR-155 expression group High vs. low 0.34 0.14–0.81 0.01 — — — 1.89 1.29–2.77 0.001
ELN Favorable vs. intermediate-I* — — — 0.5 0.32–0.79 0.003 0.42 0.28–0.63 <0.001
ELN, European LeukemiaNet; HR, hazard ratio; OR, odds ratio.
*Favorable Genetic Group is defined by CEBPA mutated or FLT3-ITD negative and NPM1 mutated status; Intermediate-I Genetic Group is defined by patients
that are not in the favorable category: CEBPA wild-type and either FLT3-ITD positive and NPM1mutated, FLT3-ITD negative and NPM1 wild-type, or FLT3-ITD
positive and NPM1 wild-type status (8).











the list of variables considered for model inclusion). For the time-to-event
end points, the proportional hazards assumption was checked for each
variable individually.
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